Merck announced that the FDA has accepted for Priority Review its New Drug Application (NDA) for an investigational intravenous solution of Noxafil (posaconazole).

RELATED: Infectious Diseases Resource Center

Noxafil Oral Suspension is already approved for prophylaxis of invasive Aspergillus and Candida infections, in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with Graft vs. Host Disease (GVHD) or those with hematologic malignancies with prolonged neutropenia due to chemotherapy.

In April, Merck announced that it had filed a New Drug Application with the FDA for an investigational, tablet formulation of Noxafil. These applications are currently under review.

For more information call (800) 672-6372 or visit